Largest Real-World Study of Its Kind Highlights How RapidAI Aids in Identifying Challenging Aneurysms

New data presented at AANS 2025 reinforces RapidAI’s clinical leadership in neurovascular care and the growing role of AI in aneurysm detection.

SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the gold standard in neurovascular AI-based clinical decision support and a leader in enterprise radiology solutions, today announced pivotal results from the most extensive real-world study to date on AI for aneurysm detection. Presented at the 2025 American Association of Neurological Surgeons (AANS) Annual Meeting, the retrospective, single-center study analyzed 11,694 consecutive CTA scans¹, demonstrating how RapidAI’s clinically validated platform, Rapid Aneurysm, can enhance diagnostic confidence and consistency, particularly in detecting nuanced or hard-to-visualize intracranial anomalies such as aneurysms when used in conjunction with standard clinical interpretation.

“Detecting aneurysms is inherently challenging, especially in a busy practice when they’re subtly positioned,” said Reza Dashti, MD, associate professor of neurosurgery and lead study investigator. “This study shows how AI can augment clinical expertise and meaningfully advance diagnostic accuracy in real-world settings.”

Presented at AANS, with additional analyses available in the abstract, the study is the most extensive retrospective, single-center AI validation for aneurysm detection to date. In the study, RapidAI helped identify nearly 23% more aneurysms than were noted on the original radiology reports. Those additional detections had a median size of 3.9 mm, large enough to warrant intervention in many cases.

For those aneurysms ≥ 3mm in size, RapidAI demonstrated stand-out performance, reinforcing the value of its deep clinical AI in enhancing diagnostic accuracy and consistency while also enhancing clinical workflows. In this subset, the platform achieved a sensitivity of 92.5% and a specificity of 96.4%.

“Given the increasing demands on today's radiology teams, this study speaks to the potential of AI to offer meaningful support and capability enhancement to the real-world challenges of manual interpretation,” said David Stoffel, MD, chief business officer at RapidAI. “This level of diagnostic aid for radiologists not only improves patient outcomes but also holds the potential to reduce downstream costs associated with missed or delayed aneurysm diagnoses.”

RapidAI’s aneurysm platform combines 3D visualization, growth tracking, and automated measurement, providing clinicians with a comprehensive view and confidence in their decisions. With this study, RapidAI not only demonstrates the value of AI in real-world care but also helps raise the bar for how hospitals and health systems can support their teams with tools for smarter, faster diagnostics.

About RapidAI

RapidAI is the world leader in AI-driven medical imaging analysis and coordinated care. With the industry’s most validated clinical AI platform, we empower care teams to rapidly, precisely, and confidently manage life-threatening conditions. Trusted by thousands of hospitals in 100+ countries, RapidAI delivers the deepest level of clinical decision support on the market to help accelerate the time to treatment and enhance patient outcomes. We go beyond the algorithm to drive care team collaboration and efficiencies that expand access to life-saving interventions. At RapidAI, we establish new standards for care teams and the patients they treat.

____________________

^1 Reza Dashti, MD "Accuracy of RapidAI’s aneurysm platform in detection of intracranial aneurysms: Retrospective analysis of consecutive series of 11,694 computed tomography angiograms (CTA)," presented at the American Association of Neurological Surgeons annual scientific meeting, 2025.